Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

EQL Pharma's Mellozzan (melatonin) tablets now available from pharmacies in Sweden

EQL Pharma
Read the release

Lund, March 22, 2021. EQL Pharma today announces that the company's Mellozzan (melatonin in tablet form) is now available in pharmacies in Sweden. Mellozzan, which is a prescription-only drug and used for treating insomnia in children with ADHD where other so-called sleep hygiene measures have been insufficient, is available at doses of 1 mg, 2 mg, 3 mg, 4 mg and 5 mg. Mellozzan is also used as a short-term treatment for jet lag in adults.

"We are pleased that Mellozzan is now available in Swedish pharmacies", says Christer Fåhraeus, CEO of EQL Pharma. "In order to get reimbursement for Mellozzan we have recently submitted an application to the Swedish Dental and Pharmaceutical Benefits Agency (TLV). Such a decision may take weeks or months".

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.